Dimensional Fund Advisors LP Acquires 9,672 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Dimensional Fund Advisors LP lifted its holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 1.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 599,812 shares of the company’s stock after acquiring an additional 9,672 shares during the period. Dimensional Fund Advisors LP owned 0.62% of Poseida Therapeutics worth $1,749,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Blair William & Co. IL boosted its stake in Poseida Therapeutics by 41.3% during the first quarter. Blair William & Co. IL now owns 965,052 shares of the company’s stock valued at $3,079,000 after buying an additional 282,310 shares during the last quarter. Vanguard Group Inc. boosted its stake in Poseida Therapeutics by 16.3% during the first quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock valued at $10,760,000 after buying an additional 473,746 shares during the last quarter. Public Employees Retirement System of Ohio boosted its stake in Poseida Therapeutics by 177.3% during the first quarter. Public Employees Retirement System of Ohio now owns 62,945 shares of the company’s stock valued at $201,000 after buying an additional 40,245 shares during the last quarter. Lazard Asset Management LLC boosted its stake in Poseida Therapeutics by 280.3% during the first quarter. Lazard Asset Management LLC now owns 28,679 shares of the company’s stock valued at $91,000 after buying an additional 21,138 shares during the last quarter. Finally, Bayesian Capital Management LP bought a new position in Poseida Therapeutics during the first quarter valued at approximately $33,000. 46.87% of the stock is owned by institutional investors.

Poseida Therapeutics Trading Up 1.6 %

Shares of PSTX stock opened at $2.51 on Friday. Poseida Therapeutics, Inc. has a 1 year low of $1.83 and a 1 year high of $4.27. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.48 and a quick ratio of 2.48. The stock’s 50 day simple moving average is $2.90 and its two-hundred day simple moving average is $2.90. The company has a market cap of $243.80 million, a PE ratio of -2.11 and a beta of 0.51.

Poseida Therapeutics (NASDAQ:PSTX) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. Poseida Therapeutics had a negative return on equity of 121.01% and a negative net margin of 127.48%. The business had revenue of $25.97 million for the quarter, compared to the consensus estimate of $13.75 million. Research analysts predict that Poseida Therapeutics, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Poseida Therapeutics in a research note on Tuesday, August 6th.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.